Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuevolution has entered into a discovery collaboration with a consortium of EpiTherapeutics, ExpreS2ion Biotechnologies and the research group of Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen), to discover small molecule drugs against epigenetic factors.
Subscribe to our email newsletter
Nuevolution said that the DKK24m ($4.48m) project is supported by the Danish High Technology Fund.
The collaboration is expected to leverage Nuevolution’s Chemetics technology to screen hundreds of millions small molecules while all biology and disease skills and expertises needed for the project to be successful are provided by EpiTherapeutics, ExpreS2ion Biotechnologies and Helin.
Nuevolution CEO Alex Gouliaev said that they were delighted with the establishment of this collaboration.
“It is with great pleasure we apply our Chemetics technology within the exciting area of epigenetics and we are looking forward to a successful collaboration,” Gouliaev said.